贝达药业：公司提出了未来五年的发展规划和重点领域

Core Insights - The company has achieved significant milestones in the field of innovative drug development over the past two decades, starting with the launch of the first small molecule targeted drug for lung cancer in China, named Kaimena, and currently has eight products on the market [2] Group 1: Company Development - The company is committed to high-quality development in response to the rapid growth of the industry, actively seeking change and improvement [2] - A five-year development plan has been proposed, focusing on key areas to drive future growth [2] Group 2: Strategic Focus - The company aims to leverage a "four-horsepower" strategy, which includes enhancing core innovation capabilities, talent resources, institutional support, and execution power [2] - The goal is to achieve breakthrough advancements in these areas to promote leapfrog development and maximize company value [2]